Study of regorafenib after lenvatinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, regorafenib, for people with liver cancer that cannot be removed by surgery and who have already tried lenvatinib. The goal is to see if regorafenib can help control the cancer after lenvatinib stops working or causes too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cancer (hepatocellular carcinoma) that cannot be removed by surgery.
- You must have taken lenvatinib before, and it either stopped working or caused side effects that made you stop.
- You must have at least one tumor that can be measured on a scan.
- Your liver function must be within a certain range (Child-Pugh class A or B7).
- You must be generally able to take care of yourself (ECOG performance status of 0-2).
- You must not have had local treatments like ablation or embolization after stopping lenvatinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
This study tests two oral targeted therapy drugs, lenvatinib and regorafenib, in people with advanced liver cancer (hepatocellular carcinoma) that has progressed after first-line immunotherapy-based treatment. The goal is to see if these drugs can control the cancer and improve outcomes.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Hear when a new Lenvatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.